vildagliptin / Generic mfg. - LARVOL DELTA

Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease via autophagy modulation. (PubMed, 3 Biotech) - "Together, these results position sitagliptin and vildagliptin as promising autophagy-modifying candidates for disease-modifying PD therapy. The online version contains supplementary material available at 10.1007/s13205-026-04761-8."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • AKT1

DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs. (PubMed, Front Cell Dev Biol) - "To further elucidate its role in the development of MAFLD, we inhibited DPP4 activity with vildagliptin (VILDA) and analyzed the global transcriptomic changes and specific gene and protein gene expression of steatosis-associated genes with and without DPP4 inhibition...Our in vitro HLC-model reproduced the DPP4-dependent aspects of the disease and responded positively to VILDA treatment. Further elucidation of the role of DPP4 in the etiology of MAFLD and other diseases is warranted."

Journal • Diabetes • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Oncology • Renal Disease • Type 2 Diabetes Mellitus • DPP4

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-, age-, and weight-related differences were noted for dulaglutide, liraglutide, semaglutide, sitagliptin, linagliptin, alogliptin, and saxagliptin. Median onset was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days), with vildagliptin latest...Musculoskeletal AEs associated with incretin therapies differ by drug class and onset timing. Vigilant monitoring is needed during early GLP-1 RA or tirzepatide therapy and later during DPP-4i use to optimize patient safety."

Adverse events • Journal • Back Pain • Diabetes • Immunology • Metabolic Disorders • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Assessing the therapeutic effects of DPP4 Inhibitors on TGF-β2-induced Lens Opacity. (PubMed, Exp Eye Res) - "In this study, we evaluated the potential efficacy of DPP4 inhibitors-specifically Sitagliptin, Saxagliptin, and Vildagliptin-in mitigating TGF-β-induced EMT in LECs. Notably, lens explant cultures treated with Vildagliptin showed a reduction in lens opacity induced by TGF-β2. These findings suggest that DPP4 inhibitors, particularly Vildagliptin, may offer a novel, non-invasive pharmacological approach to preventing PCO by targeting TGF-β signaling pathways."

Journal • Cataract • Fibrosis • Ophthalmology • FN1 • TGFB1 • VIM

Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review. (PubMed, Inflammopharmacology) - "Several medications, including rosiglitazone, amlodipine, felodipine, atorvastatin, metformin, pentoxifylline, nitazoxanide, nifuroxazide, carbocisteine, levetiracetam, topiramate, nicodamid, and vildagliptin, have been shown to have positive effects on multiple organs through their anti-inflammatory properties. Using the findings of in vitro, in vivo, and clinical investigations, the positive effects of these medications on UC are thoroughly outlined and examined in the present research. Having a better knowledge of these protective benefits and the basic mechanisms may make it possible for UC patients to take these medications effectively."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • AMPK • IL6 • mTOR • STAT3

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (clinicaltrials.gov) - P3 | N=186 | Not yet recruiting | Sponsor: Centre Hospitalier Universitaire de Besancon

New P3 trial • Diabetes • Metabolic Disorders • Nephrology • Transplantation

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (clinicaltrials.gov) - P3 | N=186 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Besancon | Trial completion date: Dec 2021 ➔ Dec 2024 | Trial primary completion date: Jul 2021 ➔ Jul 2024

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Nephrology • Transplantation

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (clinicaltrials.gov) - P3 | N=186 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Besancon | Trial completion date: Oct 2020 ➔ Dec 2021 | Trial primary completion date: Oct 2020 ➔ Jul 2021

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (clinicaltrials.gov) - P3 | N=186 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Besancon | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2020 ➔ Oct 2020 | Trial primary completion date: Jan 2018 ➔ Oct 2020

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Nephrology • Transplantation

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (clinicaltrials.gov) - P4 | N=504 | Active, not recruiting | Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia | Not yet recruiting ➔ Active, not recruiting

Biomarker • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis. (PubMed, JAMA Netw Open) - "Use of SGLT2is (dapagliflozin, empagliflozin, and canagliflozin) or DPP4is (alogliptin, linagliptin, sitagliptin, saxagliptin, and vildagliptin). In this cohort study of patients with T2D and liver cirrhosis, the use of SGLT2is was associated with substantially lower risks of adverse kidney, cardiovascular, and hepatic outcomes compared with DPP4is. These findings suggested significant cardiorenal and hepatic protection for SGLT2is in this high-risk population."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). (PubMed, Cureus) - "Baseline total cholesterol (TC), TG, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) enzyme-linked immunosorbent assay (ELISA) was done, and then, all animals were divided into six groups (M = F) of six rats each (negative control - only high-fat diet, glimepiride group, vildagliptin group, dapagliflozin group, Liv52 group, and positive control - pioglitazone group, respectively) and fed with high-fat diet and water ad libitum for six weeks. Conclusion We conclude that glimepiride, which exhibited AST and ALT reductions along with a four-point NAS reduction, offers itself as a promising drug candidate for human clinical trials for MASLD. Vildagliptin, which exhibited TC, AST, and ALT reductions but a less promising one-point NAS reduction, can also be tried in human clinical trials for MASLD."

Journal • Preclinical • Diabetes • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy. (PubMed, Tissue Cell) - "Histopathological examination supported these findings, showing significant improvement in kidney architecture. Together, our findings show that Vild and BHC-Lip work in concert to prevent DN through lowering oxidative stress and inflammation, boosting autophagy, and reducing renal structural damage."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • AKT1 • BECN1 • NES • VIM

Fluorescein-Based Charge-Transfer Fluorimetric Method for Quantification of Gliptin Drugs: Comprehensive Greenness, Blueness, and Sustainability Assessment. (PubMed, Luminescence) - "A green, sustainable, and highly sensitive fluorimetric method was developed for the quantitative determination of the antidiabetic agents alogliptin, saxagliptin, and vildagliptin in bulk powders and commercial formulations. Greenness and sustainability were evaluated using multiple assessment tools (AGSA, GAPI, AGREE, MoGAPI, Eco-scale, CACI, BAGI, CaFRI, and MA tool), confirming the eco-friendly profile of the assay. The proposed method provides a reliable, green alternative for routine quality control of gliptins in pharmaceutical preparations."

Journal

Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation. (PubMed, Int Immunopharmacol) - "These results indicate that vildagliptin-induced liver injury occurs via a mechanism whereby the covalent binding of vildagliptin induces the release of HSP40 from hepatocytes, in turn activating inflammasomes. We further demonstrated that the risk of vildagliptin-induced liver injury may be increased by impaired immune tolerance, such as that caused by the co-administration of immune checkpoint inhibitors."

Journal • Hepatology • Inflammation • Liver Failure • Oncology • DNAJB1 • IL1B

Dose-dependent effects of vildagliptin (DPP-4 inhibitor) in a scopolamine-induced memory impairment model in rats. (PubMed, Life Sci) - "These findings suggest that vildagliptin may exert protective effects against cognitive impairment by modulating cholinergic activity, inflammatory responses, and lipid peroxidation."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Diabetes • Metabolic Disorders • Oncology • Pain • Type 2 Diabetes Mellitus • IL1B • IL6 • TNFA

Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes. (PubMed, Diabetes) - "Fifteen participants with T2D, managed by diet and/or metformin, were studied on three occasions in a double-blind, randomized, crossover design. Vildagliptin selectively reduced TG(54:4) and TG(54:5) species, whereas exendin(9-39) increased total TGs and 10 individual TG species. The implications of our finding are that endogenous GLP-1 plays a physiological role in the regulation of postprandial lipid handling in T2D."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Although q12 h dosing interval reached 80% enzyme inhibition in plasma for > 25 mg doses, only the 100 mg reached this goal in muscle. The 92% enzyme inhibition was achieved in plasma for 50 and 100 mg q12 h but none of the dose regimens investigated reached this inhibition in tissues."

Journal • PK/PD data • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. (PubMed, Eur J Med Res) - "Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the DPP-4, GLP1R and KATP genes involved in Vilda's modes of action. The GG genotype for the three genes is associated with better glycemic response; however, the AA genotype of GLP1R is associated with better weight loss response. Gender has no effect; however, lower initialbody weight results in better glycemic and weight loss response."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • KCNJ11

Vildagliptin and Omarigliptin Differentially Bind to DPP-4 Homodimers and Modulate Osteoclast-Mediated Bone Resorption. (PubMed, Compr Physiol) - "In conclusion, DPP-4 inhibitors could improve bone microstructure, in part by increasing osteoblast viability and inhibiting osteoclast-mediated bone resorption. Thus, omarigliptin may offer greater benefits to diabetic patients with osteoporosis, as it also helps suppress osteoclastogenesis and bone resorption."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • CTSK • RUNX2

Biopolymeric Zein Protein Nanoparticles for Oral Vildagliptin Delivery: Fabrication, Statistical Optimization, and In Vivo Pharmacokinetics and Pharmacodynamics Insights. (PubMed, AAPS PharmSciTech) - "These findings indicated improved oral bioavailability and prolonged residence time of VLD. Additionally, the in vivo pharmacodynamic study revealed that F04 provided markedly superior and sustained hypoglycemic effects over the marketed VLD product, with higher Rmax, longer TR½, and a 2.8-fold increase in AUC(0-24H)."

Journal • PK/PD data • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. (PubMed, Drugs Real World Outcomes) - "The number of reported DPP-4 inhibitor-associated pemphigoid events increased after the revised precautions of package inserts for DPP-4 inhibitors were released."

Adverse events • Journal • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus. (PubMed, J Pharm Bioallied Sci) - "They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management. (PubMed, Int J Mol Sci) - "The latest classes of glucose-lowering drugs introduced in the clinical practice are DPP4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin), GLP-1 receptor agonists (semaglutide, liraglutide, albiglutide, dulaglutide, exenatide, and lixenatide), and SGLT-2 inhibitors (empaglifozin, canaglifozin, and dapaglifozin). Multiple lines of evidence show that all these new drugs associated with the treatment of diabetic disease have the same effectiveness as the traditional antidiabetic drugs, and excellent cardiovascular safety, highlighting their potential in significantly reducing major cardiovascular events and mortality. The aim of our review is to summarise the clinical efficacy of these recently introduced drugs to optimise treatment strategies, especially in the early phase of diabetic disease."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders

Vildagliptin-Induced Bullous Pemphigoid: A Retrospective Cohort Study. (PubMed, Australas J Dermatol) - "Non-vildagliptin BP was more likely to require systemic immunosuppression. Vildagliptin-induced BP represents a common and under-recognised clinical entity in New Zealand."

Journal • Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology